Mitomycin c is one of 683 small molecule programs targeting Ascites. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
2828 competitors in Breast Cancer
Mitomycin c
Avastin
Prolia
Cymbalta
MS Contin
Recentin
Aquasol E
Zoladex
Recombinant Human Endostatin
Tianeptine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details